http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022273764-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
filingDate 2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18a65c1eaf6420215fdbe7055d8bcfd5
publicationDate 2022-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2022273764-A1
titleOfInvention Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
abstract The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
priorityDate 2011-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2345
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406705
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395317
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396304
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393293
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13109
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID244
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6279
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16850
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412551
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9885981
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45157623
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412552
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226415140

Total number of triples: 41.